. . . . . . . . . "cyclophosphamide for injection is an alkylating drug indicated for treatment of malignant diseases 1 1 minimal change nephrotic syndrome in pediatric patients 1 2 limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established cyclophosphamide for injection is indicated for the treatment of malignant lymphomas stages iii and iv of the ann arbor staging system hodgkin s disease lymphocytic lymphoma nodular or diffuse mixed cell type lymphoma histiocytic lymphoma burkitt s lymphoma multiple myeloma leukemias chronic lymphocytic leukemia chronic granulocytic leukemia it is usually ineffective in acute blastic crisis acute myelogenous and monocytic leukemia acute lymphoblastic stem cell leukemia cyclophosphamide for injection given during remission is effective in prolonging its duration mycosis fungoides advanced disease neuroblastoma disseminated disease adenocarcinoma of the ovary retinoblastoma carcinoma of the breast cyclophosphamide for injection although effective alone in susceptible malignancies is more frequently used concurrently or sequentially with other antineoplastic drugs cyclophosphamide for injection is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established" . . . . . . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" . "iGd01bbUqidhZRS6QcKFJ4U151ng1hp/q6XhaQdMJFf/KYBn3RQZV2pcC1nwnVMJVXYsyiLxAhsdAsfFYpuVyjoOz/3232MeLelIVBB1alRpdAwbSdvOSmuVMyL2R1zMxA5qYPUfgmHSZIM00y/En3MU8Of0jvmwaKJnlKxyIFc=" . . "2021-07-03T15:53:32.804+02:00"^^ . . . . .